M42931

DEPARTMENT OF HEALTH AND HUMAN SERVICES



Food and Drug Administration Cincinnati District Office 6751 Steger Drive Cincinnati, OH 45237-3097 Telephone: (513) 679-2700 FAX: (513) 679-2772

WARNING LETTER

Cin WL – 4852-0 October 13, 2000

CERTIFIED MAIL RETURN RECEIPT REQUESTED

Dean R. Ball, D.O.
Lead Radiologist
Mahoning Valley Imaging at Healthridge Medical Center
315 Struthers – Liberty Road
Campbell, OH 44514

Facility I.D.#: 223629

Dear Dr. Ball:

We are writing to you because on October 3, 2000, your facility was inspected by a representative of the State of Ohio, acting on behalf of the Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1 finding at your facility:

Your standard operating procedures are inadequate for your facility in communicating to the patients the results of their mammograms. Your standard operating procedures fail to indicate that all of the mammography results will be communicated to the patients' referring physicians and to provide to each of the patients a lay summary report within 30 days of the mammography examinations.

21 CFR 900.12 (c)(2)(i)&(ii)

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, this condition represents a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with the Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:

- the specific steps you have taken to correct the violation noted in this letter; and
- each step your facility is taking to prevent the recurrence of similar violation.

Please include sample records with an explanation that demonstrate proper record keeping procedures that are now being followed. (Note: Patient names or identification should be deleted from any copies submitted).

Please submit your response to:

Mr. R. Terry Bolen MQSA Compliance Officer Food and Drug Administration 6751 Steger Dr. Cincinnati, OH 45237-3097

Also, please send a copy to the State radiation control office:

Ms. Terri Eckert Ohio Department of Health Radiologic Technology Section 161 South High St., Suite 400 Akron, OH 44308

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address all other obligations you may have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http://www.fda.gov/cdrh/mammography.

If you have any questions regarding this letter or how to ensure you are meeting MQSA standards, please call Mr. R. Terry Bolen at (513) 679-2700, extension 138.

Sincerely yours,

Carol A. Heppe

Acting District Director Cincinnati District Office c.
OH/TEckert

Priscilla F. Butler, M.S.
Director, Breast Imaging Accreditation Program
American College of Radiology
1891 Preston White Dr.
Reston, VA 20191